Payment overview · 2025
General Payments
$9,388.12
103 reported records · 20 companies
Healthcare provider profile · identity verified
Diane J Sutter, MD
Allopathic & Osteopathic Physicians|Obstetrics & Gynecology|Gynecology · KENMORE, NY · NPI 1447291703
Verified facts
What the public records show
CMS Open Payments records show Diane J Sutter, MD received $9,388.12 in general payments during 2025 across 103 reported records.
Astellas Pharma US Inc accounted for 76.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Intrarosa, Synthroid, Teriparatide, Trintellix, Tymlos, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Astellas Pharma Global Development reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 286 records involving 203 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Veozah by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Veozah by this doctor in 2024.
MILLICENT US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FEMRING as an associated drug or biological on 2379 records involving 1883 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Femring by this doctor in 2024.
MILLICENT US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INTRAROSA as an associated drug or biological on 6949 records involving 4373 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Intrarosa by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tymlos by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $7,220.54 | 76.9% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $470.40 | 5.0% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $262.05 | 2.8% | 20 | 2025 |
| Mayne Pharma Commercial LLC | Unresolved — no canonical attribution shown | $249.98 | 2.7% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $210.24 | 2.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $205.86 | 2.2% | 9 | 2025 |
| Astellas Pharma Global Development | Unresolved — no canonical attribution shown | $118.42 | 1.3% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $105.77 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.61 | 1.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.47 | 1.0% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $86.65 | 0.9% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $54.10 | 0.6% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $42.94 | 0.5% | 2 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $35.57 | 0.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.19 | 0.3% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.08 | 0.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.35 | 0.2% | 1 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $19.31 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.2% | 1 | 2025 |
| Cosette Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.10 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,800.00 | 5 |
| Food and Beverage | $2,556.74 | 92 |
| Travel and Lodging | $946.39 | 5 |
| Education | $84.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma Global Development, Astellas Pharma US Inc | $6,653.97 | 20 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma US Inc | $600.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $470.40 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $410.73 | 4 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $228.23 | 18 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $205.86 | 9 | 2025 |
Source payment records
|
|||||
| ANNOVERA Normalized: annovera |
Drug | Mayne Pharma Commercial LLC | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| BIJUVA Normalized: bijuva |
Drug | Mayne Pharma Commercial LLC | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| NEXTSTELLIS Normalized: nextstellis |
Drug | Mayne Pharma Commercial LLC | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $105.77 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $86.65 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.23 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $54.10 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.83 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $49.78 | 2 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $42.94 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.31 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.19 | 5 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| ORILISSA Normalized: orilissa |
Drug | ABBVIE INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| INTRAROSA Normalized: intrarosa |
Drug | MILLICENT US INC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Lynkuet Normalized: lynkuet |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Vyleesi Normalized: vyleesi |
Drug | Cosette Pharmaceuticals Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 70 | exact normalized | Medicare Part D |
| INTRAROSA intrarosa |
2025 | Intrarosa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TERIPARATIDE teriparatide |
2025 | Teriparatide | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 50 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Astellas Pharma Global Development Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 286 supporting records · 203 recipient NPIs · example record 1234123552 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
80 | 25 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| MILLICENT US INC Exact reporting entity; no affiliate inference |
2025 | FEMRING open payments reported associated product |
CMS Open Payments — General Payments 2379 supporting records · 1883 recipient NPIs · example record 1235190771 |
Femring · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| MILLICENT US INC Exact reporting entity; no affiliate inference |
2025 | INTRAROSA open payments reported associated product |
CMS Open Payments — General Payments 6949 supporting records · 4373 recipient NPIs · example record 1235190771 |
Intrarosa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Estradiol | Estradiol | 241 | 118 |
| Estradiol (Twice Weekly) | Estradiol | 236 | 83 |
| Dotti | Estradiol | 226 | 70 |
| Progesterone | Progesterone, Micronized | 219 | 62 |
| Icosapent Ethyl | Icosapent Ethyl | 116 | 44 |
| Premarin | Estrogens, Conjugated | 106 | 53 |
| Alendronate Sodium | Alendronate Sodium | 97 | 28 |
| Vascepa | Icosapent Ethyl | 81 | 33 |
| Myrbetriq | Mirabegron | 80 | 25 |
| Norethindrone Acetate | Norethindrone Acetate | 77 | 24 |
| Trazodone Hcl | Trazodone Hcl | 75 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 26 |
| Gemtesa | Vibegron | 70 | 20 |
| Estring | Estradiol | 68 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 68 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 54 | 31 |
| Valacyclovir | Valacyclovir Hcl | 53 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 50 | 12 |
| Ozempic | Semaglutide | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Fluconazole | Fluconazole | 36 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 11 |
| Veozah | Fezolinetant | 32 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Imvexxy | Estradiol | 25 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Intrarosa | Prasterone (Dhea) | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Tinidazole | Tinidazole | 21 | 15 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 20 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Dayvigo | Lemborexant | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Lyllana | Estradiol | 16 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Metronidazole | Metronidazole | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Femring | Estradiol Acetate | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Teriparatide | Teriparatide | 13 | suppressed |
| Tymlos | Abaloparatide | 13 | suppressed |
| Evamist | Estradiol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Yuvafem | Estradiol | 12 | suppressed |
| Estrogel | Estradiol | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,388.12 · 103 records | Astellas Pharma US Inc | ANNOVERA, Auvelity, BIJUVA, Cologuard Collection Kit, GEMTESA, INTRAROSA, LOREEV XR, Lynkuet, MYFEMBREE, NEXTSTELLIS, NURTEC ODT, ORILISSA, QULIPTA, Quviviq, SLYND, SYNTHROID, Symbravo, TERIPARATIDE, TRINTELLIX, Tymlos, UBRELVY, UNITHROID, VOQUEZNA, Veozah, Vyleesi, Wegovy, Xospata, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error